In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on HTG Molecular Diagnostics (NASDAQ: HTGM), with a price target of $7. The company’s shares closed yesterday at $3.90.
According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -5.8% and a 37.5% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
HTG Molecular Diagnostics has an analyst consensus of Moderate Buy, with a price target consensus of $7.
Find more picks by Best Performing Analysts >>
Based on HTG Molecular Diagnostics’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $1.92 million. In comparison, last year the company had a GAAP net loss of $5.82 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
HTG Molecular Diagnostics, Inc. engages in the provision of molecular technology solutions that facilitates molecular profiling. Its customers include biopharmaceutical companies, academic research centers, and molecular testing laboratories. The company was founded by Bruce E. Seligmann in October 1997 and is headquartered in Tucson, AZ.
Read More on HTGM:
